Abstracts tagged "Demographics"

Abstract Number: 1452 • ACR Convergence 2025
Clinical and Demographic Characteristics of Treatment-Refractory Axial Spondyloarthritis: Data from the Greek AxSpA Registry
Nikolaos Kougkas¹, Konstantinos Tsafis², Dimitrios Deligeorgakis³, Vasileios Papadopoulos⁴, Nikolaos Fytanidis⁵, Michail Krikelis⁶, Evangelia Mole⁷, Sousana Gazi⁷, Nikolaos Koletsos⁸, EVRIPIDIS KALTSONOUDIS⁹, Paraskevi V Voulgari¹⁰, Anastasios Karamanakos¹¹, Maria Pappa¹², Maria Tektonidou¹³, Petros Sfikakis¹⁴, Kalliopi Klavdianou¹⁵, aggelos Banos¹⁶, Eleni Kalavri¹⁷, Konstantinos Kottas¹⁸, Gkikas Katsifis¹⁸, MARIA KONSTA¹⁹, Eleftheria Grika²⁰, Charalampos Sfontouris²⁰, Evgenia Mavrea²¹, Christos Koutsianas²², Evangelia Kataxaki²³, Eleni Sampatakaki²⁴, Konstantina Zoupidou²⁵, Pelagia Katsimpri²⁶, Alexios Iliopoulos²⁷, Georgios Iliopoulos²⁸, Dimitrios Daousis²⁹, Ilias Bournazos³⁰, DIMITRIOS KAROKIS³¹, Dimos Patrikos³², Theodoros Dimitroulas³, Dimitrios Vassilopoulos²¹, George E Fragoulis³³ and Charalampos Papagoras³⁴, ¹⁴th Department of Internal Medicine, Aristotle University, Thessaloniki, Thessaloniki, Greece, ²Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, Fourth Department of Internal Medicine, Thessaloniki, Greece, Thessaloniki, Thessaloniki, Greece, ³Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, Fourth Department of Internal Medicine, Thessaloniki, Greece, Thessaloniki, Greece, ⁴Department of Medicine Democritus University of Thrace, Laboratory of Anatomy, Alexandroupolis, Greece, Alexandroupolis, Evros, Greece, ⁵University Hospital of Alexandroupolis, Democritus University of Thrace, First Department of Internal Medicine, Alexandroupolis, Greece, Alexandroupolis, Greece, ⁶KAT Hospital, Athens, Department of Rheumatology, Athens, Greece,, Athens, Attiki, Greece, ⁷Rheumatology department, KAT General Hospital of Attica, Athens, Attiki, Greece, ⁸School of Health Sciences, Faculty of Medicine, University of Ioannina, Department of Rheumatology, Ioannina, Greece, Ioannina, Ioannina, Greece, ⁹Rheumatology Clinic, University of Ioannina, IOANNINA, Ioannina, Greece, ¹⁰Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Ioannina, Greece, ¹¹Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Laiko”, First Department of Propedeutic and Internal Medicine, Athens, Greece, Athens, Greece, ¹²Rheumatology and Clinical Immunology Unit, ⁴th Department of Internal Medicine, Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ¹³National and Kapodistrian University of Athens, Athens, Greece, ¹⁴NKUA - SCHOOL OF MEDICINE, Athens, Greece, ¹⁵Asklepieion" General Hospital, Athens, Department of Rheumatology, Αthens, Greece, Kaisariani Athens, Greece, ¹⁶Asklepieion" General Hospital, Athens, Department of Rheumatology, Αthens, Greece, Athens, Attiki, Greece, ¹⁷"Asklepieion" General Hospital, Athens, Department of Rheumatology, Αthens, Greece, Athens, Greece, ¹⁸Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece, Athens, Greece, ¹⁹Sismanoglion Hospital, Athens, Greece, Marousi, Attiki, Greece, ²⁰Evaggelismos Athens General Hospital, Department of Rheumatology, Athens, Greece, Athens, Greece, ²¹Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Hippokration”, Clinical Immunology-Rheumatology Unit, ²nd Department of Medicine and Laboratory, Athens, Greece, Athens, Greece, ²²Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Hippokration”, Athens, Greece, ²³General Hospital Elefsinas Thriaseio,Attica, Rheumatology Department, Athens, Greece, Athens, Greece, ²⁴Joint Academic Rheumatology Program, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, ⁴th Department of Internal Medicine, Athens, Greece, Athens, Attiki, Greece, ²⁵Joint Academic Rheumatology Program, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, ⁴th Department of Internal Medicine, Athens, Greece, Athens, Greece, ²⁶Joint Rheumatology Program, University of Athens Medical School, Athens, Greece, ²⁷⁴¹⁷ Army Share Fund Hospital (NIMTS), Department of Rheumatology, Athens, Greece, ZOGRAFOU, Greece, ²⁸Patras University Hospital, University of Patras Medical School, Department of Rheumatology, Patras, Greece, Patras, Akhaia, Greece, ²⁹Patras University Hospital, University of Patras Medical School, Department of Rheumatology, Patras, Greece, Patra, Greece, ³⁰Private practice, Athens, Greece, Athens, Greece, ³¹Private practice, Patras, Greece, Patras, Greece, ³²Private practice, Athens, Greece, Ag. Paraskevi, Greece, ³³First Department of Propedeutic and Internal Medicine, Joint Academic Rheumatology program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ³⁴First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Evros, Greece
Background/Purpose: Axial spondyloarthritis (AxSpA) is a chronic inflammatory disease that significantly impairs quality of life. Although biologic and targeted synthetic DMARDs (b/tsDMARDs) have improved disease…
Abstract Number: 1394 • ACR Convergence 2025
Burden of Comorbidities Across EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains: Treatment Prevalence Among Commercially Insured Sjögren’s Patients in the United States
Minoti Ganguli, Annie Kilby, Ahva Shahabi and Tsu-Chieh Jay Lin, Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sjögren’s disease (SjD) is a systemic disorder characterized by exocrine gland inflammation, leading to dry eyes/mouth, and multiple organ systems involvement1. The European League…
Abstract Number: 1393 • ACR Convergence 2025
Prevalence of Sjögren’s Disease in the United States – A Retrospective Cohort Study Among a Commercially Insured Population (2019-2023)
Minoti Ganguli, Annie Kilby, Ahva Shahabi and Tsu-Chieh Jay Lin, Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune condition characterized by diverse clinical manifestations, which often complicates diagnosis and disease management1. Previous epidemiological estimates of…
Abstract Number: 1263 • ACR Convergence 2025
Health Literacy diversity among rheumatology patients: insights from a tertiary rheumatology centre
Cristina Calomarde-Gomez¹, Mrinalini Dey², Chris Wincup³, María Alonso de Francisco⁴, Christina Cheng⁵, Richard Osborne⁵ and Elena Nikiphorou⁶, ¹Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ²Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ³King's College Hospital, London, United Kingdom, ⁴H. U. Puerta de Hierro Majadahonda, Tres Cantos, Spain, ⁵La Trobe University, Melbourne, Victoria, Australia, ⁶King's College London, London, United Kingdom
Background/Purpose: Health literacy is a potential social determinant of health, fundamental to patient engagement, clinical communication, and long-term outcomes of disease. Understanding health literacy at…
Abstract Number: 1153 • ACR Convergence 2025
New Disease Classification in the Block? A 5-year Retrospective Review on Clinical Profiles and Mortality Outcomes of Patients Presenting with Hematoinflammatory Syndromes at a University Center in Florida
Cristine Kuzhuppilly Arcilla¹, Gabriel Kirsch², Michael Cargill² and Gurjit Kaeley³, ¹University of Florida Jacksonville, Jacksonville, FL, ²University of Florida - Jacksonville, Jacksonville, FL, ³UF COM-J, Ponte Vedra Beach, FL
Background/Purpose: The novel diagnosis of VEXAS in 2020 led to the proposed possibility of a new category of hematoinflammatory syndromes linking clinically overlapping hematologic and…
Abstract Number: 2666 • ACR Convergence 2025
Rare TNFAIP3 Hypomorphic Variants are a Massively Underestimated Driver of Human Autoinflammatory Disease
Danica Lee¹, Urekha Karri², Yiming Luo³, Kader Cetin Gedik⁴, Manuel Carpio Tumba⁵, Prabal Chhibbar⁶, Priyamvada Roy⁶, Guido Falduto⁷, Jishnu Das⁵ and Daniella Schwartz⁵, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²School of public health, Pittsburgh, PA, ³Columbia University, New York, NY, ⁴UPMC Children's Hospital of Pittsburgh/University of Pittsburgh, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶University of Pittsburgh School of Medicine, Pittsburgh, ⁷University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: TNFAIP3 encodes the ubiquitin editing enzyme A20, which inhibits multiple proinflammatory signaling pathways. Heterozygous germline mutations in TNFAIP3 cause the autoinflammatory disease Haploinsufficiency of…
Abstract Number: 1071 • ACR Convergence 2025
Depression and Mental Health Service Gaps in Autoimmune Disease: Insights from a Simulated BRFSS Dataset
Malay Rathod¹, Shivani Modi², Veera Durga Vaishnavi Kurra³, Karan Yagnik⁴ and Doantrnag Du⁴, ¹Monmouth Medical Center, Ewing, NJ, ²Jefferson Einstein Montgomery Hospital, Ewign, NJ, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Monmouth Medical Center, Long Branch, NJ
Background/Purpose: Autoimmune diseases are complex conditions that may predispose individuals to an increased mental health burden, including depression. The immune system leads to inflammation in…
Abstract Number: 2615 • ACR Convergence 2025
The Cost of Complexity: Financial Toxicity in Rheumatic Disease, Cancer, and Their Intersection
Manush Sondhi¹, Bhavik Bansal², Hemant Khandelia¹, Jiha Lee³, Sebastian E Sattui⁴, Siddharth Singh⁵ and Namrata Singh⁶, ¹University of Washington, Seattle, WA, ²UT Southwestern Medical Center, Dallas, ³University of Michigan, Ann Arbor, MI, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵University of California San Diego, San Diego, CA, ⁶University of Washington, Bellevue, WA
Background/Purpose: Financial toxicity (FT) is the financial burden of accessing health care, well known in cancer and increasingly seen in rheumatic disease (RD). We compared…
Abstract Number: 1012 • ACR Convergence 2025
Racial and Gender Disparities in Gout Clinical Trials
Fizza Zulfiqar¹, Dania Kaur², Meaghan Bethea³, Taylor Spencer⁴, Samhitha Bitla⁵, Abhinav Vyas⁶ and Camelia Arsene⁷, ¹Trinity Health Oakland/Wayne State University, Pontiac, MI, ²North Alabama Medical Center, Muscle Shoals, AL, ³Trinity Health Oakland Hopsital, Pontiac, MI, ⁴Trinity Health Oaklnd Hospital, Pontiac, MI, ⁵Trinity Health Oakland Hospital, Pontiac, MI, ⁶Vanderbilt University, Nashvile, TN, ⁷Trinity Health Oakland Hospital, Pontiac
Background/Purpose: To develop effective novel treatment strategies for Gout disease that cater to patients from diverse backgrounds, it is crucial that all racial groups, without…
Abstract Number: 2558 • ACR Convergence 2025
Impact of Social Determinants of Health on Patient Perceptions of Home Infusion Therapy in the Treatment of Rheumatologic Conditions
Leslie Myers¹, Elizabeth Neal², Edward O'Bryan¹, Michele Way³ and Timothy Walton¹, ¹CSI Pharmacy, Nash, ²CSI Pharmacy, Nash, TX, ³CSI Pharmacy, Olathe, KS
Background/Purpose: Home infusion therapy is an established alternative site of care for patients requiring administration of infusion medications through a needle or catheter. Supported by…
Abstract Number: 0703 • ACR Convergence 2025
Trends and Disparities in Systemic Sclerosis-related Mortality Rates in the United States from 1999 to 2023
Nicolas Barnechea Alvarado¹, Khadija Mohib¹, Rameez Qasim² and Muhammad Ali³, ¹Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, ²Allama Iqbal Medical College Lahore, Lahore, Pakistan, ³Dow International Medical College, Karachi, Sindh, Pakistan
Background/Purpose: Systemic sclerosis is one of the most fatal rheumatologic diseases, with significantly higher mortality rates compared to the general population, likely due to its…
Abstract Number: 2537 • ACR Convergence 2025
Variation in Treatment Approaches in IgA-Vasculitis Among Pediatricians and Pediatric rheumatologists: A Cross-Sectional International Survey
Merav Heshin Bekenstein¹, Tali Elbaz², Yael Illous² and Barak Kandell³, ¹Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, ²School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv, Israel, ³The Academic College of Tel Aviv-Yafo, Tel Aviv, Israel
Background/Purpose: IgA Vasculitis (IgAV) is the most common small-vessel vasculitis in children. Although there is no evidence-based recommendations for treating IgAV, the European SHARE recommendations…
Abstract Number: 0580 • ACR Convergence 2025
Persistence and Disease Activity Control among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy
Philip J. Mease¹, Nicole Middaugh², Yolanda Muñoz Maldonado², Chao Song³, Melissa Eliot², Robert Low³ and Alexis Ogdie⁴, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³UCB, Smyrna, GA, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic disease that causes inflammation of the joints, entheses, spine, skin, and nails.1 While available advanced treatments (txs) for…
Abstract Number: 2099 • ACR Convergence 2025
Incidence and Prevalence of Osteoarthritis in the United States Compared to Global Trends: Insights from the Global Burden of Disease Study (1990–2021)
Khadija Mohib¹, Rameez Qasim², Nicolas Barnechea Alvarado¹, ZAUHA FAWAD MEMON³ and Muhammad Asjad Saleem⁴, ¹Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, ²Allama Iqbal Medical College Lahore, Lahore, Pakistan, ³Peoples University of Medical and Health Sciences for Women, Tando Allahyar, Sindh, Pakistan, ⁴Indus Hospital Karachi, Karachi
Background/Purpose: Osteoarthritis (OA) is the most prevalent musculoskeletal condition, predominantly affecting individuals over the age of 55. According to the World Health Organization (WHO), OA…
Abstract Number: 0607 • ACR Convergence 2025
Age at Diagnosis of SLE has Increased in a United States Longitudinal Cohort
Daniel Goldman¹, Andrea Fava², Laurence Magder³ and Michelle Petri¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: The demographics of our lupus cohort have shifted over the decades towards an older population. While much of the shift can be attributed to…

1
2
3
…
7
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].